Showing 321-330 of 7562 results for "".
Diagnosing Allergic Contact Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/diagnosing-allergic-contact-dermatitis/20460/Three cases of ACD reactions to over-the-counter antibiotic ointments.Pearls for Management of Pediatric Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/pearls-pediatric-management-atopic-dermatitis/27122/At the recently held 2024 American Academy of Dermatology (AAD) Innovation Academy dermatologist Lisa Swanson, MD, FAAD, presented new insights into pediatric atopic dermatitis (AD), emphasizing its wide-ranging impact on children's health, including increased risks of food allergies, infections, anAAD Wrap: What To Know from Dermatology’s Biggest Meeting
https://practicaldermatology.com/issues/april-2025/aad-wrap-what-to-know-from-dermatologys-biggest-meeting/35623/The 2025 American Academy of Dermatology (AAD) Annual Meeting brought together the dermatology community this past March to exchange groundbreaking research, innovative treatments, and technological advancements. For 4 days in Orlando, the meeting served as the hub of the dermatology profession, delThe Impact of Clascoterone Topical Cream, 1%: The US Experience 4 Years After Approval and Clinical Expectations for Acne Patients in Other Regions of the World
https://practicaldermatology.com/topics/acne-rosacea/Impact-Clascoterone-Topical-Cream/32830/Clascoterone topical cream, 1% (Winlevi), approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older. The safety and efficacy were supported by two succeVtama Approved for AD in Adults and Children
https://practicaldermatology.com/series/dermwire-tv/vtama-approved-ad-adults-and-children/30079/In this week's DermwireTV, the FDA approves Vtama (tapinarof cream 0.1%) for atopic dermatitis in adults and children; the FDA approves Nemluvio (nemolizumab) for moderate-to-severe AD; and the president of Nuance Medical discusses the acquisition of scar treatment brand, Biocorneum.Science of Skincare Summit 2024: On the FDA Approval of Emrosi for Rosacea
https://practicaldermatology.com/conferences/science-skincare-summit-2024/science-of-skincare-summit-2024-on-the-fda-approval-of-emrosi-for-rosacea/29276/At the Science of Skincare Summit in Austin, Practical Dermatology caught up with Chief Medical Editor Neal Bhatia, MD, and James Del Rosso, DO, a dermatologist and Editor in Chief of Clinical Dermatology at the Journal of Clinical and Aesthetic Dermatology (JCAD), who shared insights and thoughts oDermWire TV Extra: SDPA President Amber Blair, PA-C, Previews Her New Column
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-extra-sdpa-president-amber-blair-pa-c-previews-her-new-column/27001/Amber Blair, PA-C, president of the Society of Dermatology Physician Associates, discusses important initiatives that she plans to cover in her new quarterly column in Practical Dermatology.DermWire TV: Maui Derm Highlights, Plus New and Emerging Treatments for HS and Acne
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-maui-derm-highlights-plus-new-and-emerging-treatments-for-hs-and-acne/20258/In this episode of DermWire TV, we recap the biggest news from Maui Derm 2024, including safety and efficacy studies on bimekizumab, deucravacitinib, and upadacitinib. Also from Maui Derm, Raj Chovatiya, MD, PhD, highlights new therapies to treat hidradenitis suppurativa and Julie Harper, MD, highliAngioleiomyoma in a Rare Location
https://practicaldermatology.com/topics/other-dermatology/angioleiomyoma-in-a-rare-location/24012/A minimally invasive treatment is used to treat a tumor in a cosmetically sensitive area.Advances in Topicals for Skin Conditions
https://practicaldermatology.com/topics/psoriasis/advances-in-topicals-for-skin-conditions/20197/There are more topicals available today than ever before for acne, rosacea, and psoriasis, and even more are coming down the pike. Larry Green, MD, reviews the current topical landscape in dermatology and previews what’s in the pipeline.